If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIconic Labs Regulatory News (ICON)

Share Price Information for Iconic Labs (ICON)

Share Price is delayed by 15 minutes
Get Live Data
1.75    -0.10 (-5.41%)
Bid:
1.60
Ask:
1.90
Spread: 0.30 (18.75%)
Market Cap: £287.18k
ICON Live PriceLast checked at - London Stock Exchange

Intraday Iconic Labs Share Chart

Statement re CVA

12 Sep 2023 08:45

RNS Number : 1540M
Iconic Labs PLC
12 September 2023
 

 

 

 12 September 2023

Iconic Labs PLC

 

("Iconic" or the "Company")

 

Allotment of Shares and Conclusion of CVA

 

Iconic Labs PLC (LSE: ICON) today announces that 83,256 ordinary shares of £0.1 were allotted to the unsecured creditors (the "Unsecured Creditors") in accordance with the Creditors Voluntary Arrangement (CVA) dated 22 September 2022.

 

Application is being made for 83,256 new Ordinary Shares to be admitted to trading on the Main Market of the London Stock Exchange which is expected to be on or around 15 September 2023. These shares rank pari passu with the existing Ordinary Shares of the Company.

 

Following the issue of these shares, the Company's issued ordinary share capital shall consist of 5,003,275 Ordinary Shares. The figure of 5,003,275 represents the total voting rights in the Company and should be used by shareholders as the denominator for the calculation by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance & Transparency Rules.

 

Brad Taylor, Chief Executive Officer of Iconic Labs, commented:

 

"We are pleased to announce the allotment of shares to the Unsecured Creditors satisfies the final condition to bring the CVA to a successful conclusion. Once the CVA is discharged, Iconic will be well positioned to focus on its business goals. The Board remains committed to delivering value to our shareholders and stakeholders alike."

 

- Ends -

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

 

For any further information or enquiries please contact:

 

Iconic Labs

Brad Taylor, Chief Executive Officer

Tel: +44 (0) 7462 156238

ir@iconiclabs.co.uk

Novum Securities Limited

David Coffman / Daniel Harris

Tel: +44 (0) 20 7399 9400

 

Yellow Jersey PR

Sarah Hollins

Annabelle Wills

Bessie Elliot

 

Tel: +44 (0) 20 3004 9512

iconic@yellowjerseypr.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STRUUSBRORUKARR
Date   Source Headline
28th Feb 20232:05 pmRNSSecond Price Monitoring Extn
28th Feb 20232:00 pmRNSPrice Monitoring Extension
28th Feb 20237:57 amRNSChange of Registered Office
28th Feb 20237:56 amRNSTotal Voting Rights
24th Feb 20234:35 pmRNSPrice Monitoring Extension
22nd Feb 20232:05 pmRNSSecond Price Monitoring Extn
22nd Feb 20232:00 pmRNSPrice Monitoring Extension
22nd Feb 20239:05 amRNSSecond Price Monitoring Extn
22nd Feb 20239:00 amRNSPrice Monitoring Extension
21st Feb 20234:40 pmRNSSecond Price Monitoring Extn
21st Feb 20234:35 pmRNSPrice Monitoring Extension
21st Feb 20232:05 pmRNSSecond Price Monitoring Extn
21st Feb 20232:00 pmRNSPrice Monitoring Extension
20th Feb 20234:35 pmRNSPrice Monitoring Extension
20th Feb 20237:49 amRNSDirector Appointment
16th Feb 20239:05 amRNSSecond Price Monitoring Extn
16th Feb 20239:00 amRNSPrice Monitoring Extension
15th Feb 20233:00 pmRNSTR-1 notification
15th Feb 20233:00 pmRNSTR-1 notification
15th Feb 20233:00 pmRNSTR-1 notification
15th Feb 20233:00 pmRNSTR-1 notification
15th Feb 20233:00 pmRNSTR1 notification
15th Feb 20233:00 pmRNSTR1 notification
10th Feb 20232:05 pmRNSSecond Price Monitoring Extn
10th Feb 20232:00 pmRNSPrice Monitoring Extension
10th Feb 20239:05 amRNSSecond Price Monitoring Extn
10th Feb 20239:00 amRNSPrice Monitoring Extension
10th Feb 20237:00 amRNSSubscription of Convertible Notes
9th Feb 20232:00 pmRNSPrice Monitoring Extension
9th Feb 20231:04 pmRNSConversion of Securities
8th Feb 20234:40 pmRNSSecond Price Monitoring Extn
8th Feb 20234:35 pmRNSPrice Monitoring Extension
8th Feb 20232:05 pmRNSSecond Price Monitoring Extn
8th Feb 20232:00 pmRNSPrice Monitoring Extension
6th Feb 20237:18 amRNSConversion of Notes
2nd Feb 20237:55 amRNSRestructuring Update
31st Jan 20232:05 pmRNSSecond Price Monitoring Extn
31st Jan 20232:00 pmRNSPrice Monitoring Extension
31st Jan 202311:05 amRNSSecond Price Monitoring Extn
31st Jan 202311:00 amRNSPrice Monitoring Extension
31st Jan 20238:52 amRNSTotal Voting Rights
30th Jan 20234:40 pmRNSSecond Price Monitoring Extn
30th Jan 20234:35 pmRNSPrice Monitoring Extension
30th Jan 20238:04 amRNSConversion of Securities & Resignation of Director
27th Jan 202311:05 amRNSSecond Price Monitoring Extn
27th Jan 202311:00 amRNSPrice Monitoring Extension
25th Jan 202312:08 pmRNSRestoration of Trading
25th Jan 20239:00 amRNSPrice Monitoring Extension
24th Jan 20234:40 pmRNSSecond Price Monitoring Extn
24th Jan 20234:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.